NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Agenus Inc. (AGEN) Stock Analysis

Agenus Inc. (AGEN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

AGEN

$8.24

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AGEN with… →

AGEN Key Statistics

As of Sep 4, 2026
Trading
Open
$8.14
Previous Close
$8.24
Day's Range
7.99–8.38
52-Week Range
2.71–8.85
Volume
986.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.40
Valuation
Market Cap
$370.88M
P/E Ratio
2.76
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.44
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.80
EPS (ttm)Profit attributable to each share over the last twelve months.
2.99
Financials (FY)
Revenue (FY)
$114.20M+10.37%
Net Income (FY)
$115.00K
Profit marginThe share of revenue left as profit after all costs and taxes.
69.34%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
45.01M
1-Year Return
+92.07%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
4.20M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AGEN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+162.42%
2025+14.60%
2024−83.49%
2023−64.76%
2022−25.47%
2021+1.26%
2020−21.87%
2019+71.01%
2018−26.99%
2017−20.87%
2016 (partial year)−32.90%

As of September 4, 2026.

AGEN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$114.20M$115.00K0.1%
2024$103.46M−$227.21M−219.6%
2023$156.31M−$245.76M−157.2%
2022$98.02M−$220.07M−224.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$114.20M$33.84M−$20.56M$115.00K0.1%
2024$103.46M−$52.55M−$124.43M−$227.21M−219.6%
2023$156.31M−$81.37M−$160.11M−$245.76M−157.2%
2022$98.02M−$99.24M−$180.24M−$220.07M−224.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AGEN Valuation vs Biotechnology Median

Median of 656 stocks
MetricAGENBiotechnology medianvs median
P/E2.7612.570.2x the median
P/S ratio2.8015.260.2x the median
Profit margin69.34%0.00%69.3 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Agenus Inc. (AGEN) at $370.88M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 81 employees.

The 52-week range on file runs from $2.71 to $8.85. AGEN last closed at $8.24 on September 4, 2026. The close was unchanged from the previous session. The latest close sits 204.06% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $114.20M. That is +10.37% against the prior fiscal year, when revenue was $103.46M. The same year closed with net income of $115.00K. Profit margin runs at 69.34%. That is 69.3 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 2.99.

Across the 4 fiscal years on file, revenue moves from $98.02M in 2022 to $114.20M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 2.76. That is 0.2 times the Biotechnology median of 12.57. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.44. Measured against sales, the shares trade at 2.8 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +92.07%. Measured over 10 years, that is −23.53% a year compounded. Beta against the wider market is reported at 1.4. Annualized volatility over the trailing 10 years is 88.18%.

Growth & Income

No dividend is on file for AGEN.

Across the complete calendar years on file, 2019 returned +71.01% and 2024 returned −83.49%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the price is +162.42% year to date.

Peer Comparison

Agenus Inc. (AGEN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Agenus Inc. AGEN $370.88M 2.8
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Agenus Inc. trades at a P/E of 2.8.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Agenus Inc.

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Visit website →